Please login to the form below

Not currently logged in


This page shows the latest evolocumab news and features for those working in and with pharma, biotech and healthcare.

Dupixent bounce-back helps stem diabetes declines at Sanofi

Dupixent bounce-back helps stem diabetes declines at Sanofi

At the moment, Sanofi is losing out in the PCSK9 inhibitor market to rival Amgen, whose Repatha (evolocumab) made second quarter sales of $148m, also well shy of early projections.

Latest news

More from news
Approximately 11 fully matching, plus 50 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...